OliPass Corp
KOSDAQ:244460
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1 651
3 560
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| KR |
O
|
OliPass Corp
KOSDAQ:244460
|
9B KRW |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
385.5B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
186.7B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
162.9B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
118.7B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.6B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
87B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
43B EUR |
Loading...
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
48.8B USD |
Loading...
|
Market Distribution
| Min | -163 055.6% |
| 30th Percentile | -2.2% |
| Median | 2.7% |
| 70th Percentile | 6.8% |
| Max | 22 874.8% |
Other Profitability Ratios
OliPass Corp
Glance View
OliPass Corp. develops biological products. The company is headquartered in Yongin, Gyeonggi-Do. The company went IPO on 2019-09-20. The firm principally manufactures and sells nonopioid analgesic, hyperlipidemia medicine, ocular angiogenesis inhibitor, duchenne dystrophy medicine, cancer immunotherapy medicine and other products. In addition, the Company researches, develops and sells functional cosmetics through the artificial gene platform technology.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for OliPass Corp is -1 249.2%, which is above its 3-year median of -2 430.7%.
Over the last 3 years, OliPass Corp’s Operating Margin has increased from -1 409.6% to -1 249.2%. During this period, it reached a low of -16 230.6% on Mar 31, 2023 and a high of -237.8% on Dec 31, 2023.